<DOC>
	<DOCNO>NCT02713997</DOCNO>
	<brief_summary>Patients severe chronic pancreatitis may candidate pancreas remove islet transplant liver reduce risk diabetes mellitus , procedure call total pancreatectomy islet autotransplant ( TPIAT ) . However , half patient TPIAT need remain supplemental insulin life-long procedure . We study therapy may reduce damage transplant islet , thereby improve long-term outcome . Two promise anti-inflammatory therapy available protect islet damage time transplant : ( 1 ) Tumor Necrosis Factor ( TNF ) -alpha inhibitor etanercept ( 2 ) serine protease inhibitor alpha-1 antitrypsin . Both agent commercially available clinical trial . Proof-of-principle etanercept demonstrate type 1 diabetic allotransplant recipient , 10 day course etanercept early post-transplant significantly improve long-term insulin independence , due good survival transplant beta cell mass engraftment period . Alpha-1 antitrypsin ( A1AT ) reduce inflammatory cytokine , protect cytokine-induced beta cell apoptosis , prolongs islet graft survival mouse intraportal IAT non-human primate . This initial 3-arm drug-treatment clinical trial investigate use Etanercept A1AT improve IAT function 90 day 1 2 year post-TPIAT compare standard care . Forty-five patient undergo TPIAT randomize 1:1:1 receive either : 1 ) etanercept ( 50 mg day 0 ; 25 mg day 3 , 7 , 10 , 14 , 21 ) , 2 ) alpha-1 antitrypsin ( 90 mg/kg IV day -1 , +3 , 7 , 14 , 21 , 28 ) 3 ) standard care . Patients mechanistic assessment draw early post-operative period include inflammatory cytokine chemokines measure beta cell loss . Metabolic test occur 90 , 365 , 730 day post-TPIAT , include mixed meal tolerance testing , IV glucose tolerance testing , glucose-potentiated arginine-induced insulin secretion ( GPAIS ) .</brief_summary>
	<brief_title>Anti-inflammatory Therapy Improve Outcomes After TPIAT</brief_title>
	<detailed_description>For patient severe pancreatitis refractory medical endoscopic therapy , total pancreatectomy ( TP ) islet autotransplantation ( IAT ) may consider . While 90 % TPIAT recipients function transplant islet graft , 1/3rd come completely insulin . The long-term goal propose research develop new therapy increase number patient non-diabetic following islet autotransplant . Such therapy may also benefit recipient islet allotransplant type 1 diabetes . Following islet transplantation , islet must acutely survive stress procedure , must engraft liver establish vascular supply . The great functional islet mass engraft , low risk post-operative diabetes . It estimate half islet mass may lose early post-transplant period islet transplant recipient . Beta cell apoptosis common first month post-transplant upregulated presence inflammatory cytokine TNF-alpha . Thus , major contributor islet loss inflammatory damage sustain transplanted islet early post-transplant period ; propose directly target destructive process . Two promise anti-inflammatory therapy available address problem : ( 1 ) TNF-alpha inhibitor etanercept ( 2 ) serine protease inhibitor alpha-1 antitrypsin . Both agent commercially available clinical trial . Proof-of-principle etanercept demonstrate type 1 diabetic allotransplant recipient , 10 day course etanercept early post-transplant significantly improve long-term insulin independence , due good survival transplant beta cell mass engraftment period . Alpha-1 antitrypsin ( A1AT ) reduce inflammatory cytokine , protect cytokine-induced beta cell apoptosis , prolongs islet graft survival mouse intraportal IAT non-human primate . This initial 3-arm drug-treatment clinical trial investigate use Etanercept A1AT improve IAT function 90 day 1 2 year post-TPIAT compare standard care . Forty-five patient undergo TPIAT randomize 1:1:1 receive either : 1 ) etanercept ( 50 mg day 0 ; 25 mg day 3 , 7 , 10 , 14 , 21 ) , 2 ) alpha-1 antitrypsin ( 90 mg/kg IV day -1 , +3 , 7 , 14 , 21 , 28 ) 3 ) standard care . Patients mechanistic assessment draw early post-operative period include inflammatory cytokine chemokines measure beta cell loss . Metabolic test occur 90 , 365 , 730 day post-TPIAT , include mixed meal tolerance testing , IV glucose tolerance testing , glucose-potentiated arginine-induced insulin secretion ( GPAIS ) . The latter measure maximally stimulate acute C-peptide response ( ACRmax ) best estimate islet mass primary endpoint ( day 90 ) study . Results use select promising agent future study randomize , blind multi-center clinical trial .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>1 . Age 18 68 year . . 2 . Scheduled total pancreatectomy IAT University Minnesota ( UM ) . All patient approve pancreatectomy IAT UM review multidisciplinary committee include surgeon , gastroenterologist specialize pancreatic disease , pain specialist , psychologist , endocrinologist confirm diagnosis chronic pancreatitis candidate suitability surgery . 3 . Able provide inform consent 1 . Preexisting diagnosis diabetes mellitus , fast blood glucose &gt; 115 mg/dl , hemoglobin A1c level &gt; 6.0 % evidence inadequate betacell mass . 2 . Use follow treatment 30 day prior enrollment : insulin , metformin , sulfonylurea , glinides , thiazolidinediones , Glucagon Like Peptide ( GLP ) 1 agonist , dipeptidyl peptidase ( DPP4 ) inhibitor , amylin . 3 . Immunoglobulin ( IgA ) deficiency ( serum level &lt; 5 mg/dL ) , associate hypersensitivity alpha1 antitrypsin . 4 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 time upper limit normal ( ULN ) . Bilirubin &gt; ULN , unless due benign diagnosis Gilbert 's . 5 . Known history human immunodeficiency virus ( HIV ) infection , hepatitis B ( chronic ) , hepatitis C ( chronic ) . 6 . History tuberculosis ( TB ) ( latent active disease ) , positive TB skin test . 7 . History symptomatic fungal lung infection . 8 . History multiple sclerosis , transverse myelitis , Guillain Barre , suspect demyelinate disease , due risk exacerbation condition use etanercept ; prior history systemic lupus erythematosus 9 . Any following hematologic abnormality : severe anemia ( hgb &lt; 10 g/dL ) , thrombocytopenia ( &lt; 150/mm3 ) , neutropenia ( &lt; 1.0 x109/L ) . 10 . Current use expect use oral injected corticosteroid , mediation likely affect glucose tolerance . However , use hydrocortisone physiologic replacement , use topical , inhaled , intranasal glucocorticoid permit . 11 . Current expect use immunosuppressive agent . 12 . Known hypersensitivity etanercept A1AT . 13 . Any condition likely , opinion patient 's medical provider , necessitate use TNF alpha therapeutically future ( psoriatic arthritis ) . 14 . Known coagulopathy , need anticoagulant therapy preoperatively ( coumadin , enoxaparin ) , history pulmonary embolism . 15 . For female , plan become pregnant unwillingness use birth control study duration . 16 . Inability comply study protocol . 17 . Untreated psychiatric illness may interfere ability give inform consent , developmental delay neurocognitive disorder impair patient 's ability consent behalf . 18 . Any medical condition , opinion investigator , may interfere patient 's ability successfully safely complete trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>